|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02279 YONGHE MEDICAL
Nominal 
2.740 +0.030 (+1.107%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 861,550 | -4.294% | 1,804,498 | 1,777,258 | 1,412,791 | 2,168,580 |
| Cost of Sales | (311,227) | -16.058% | (720,286) | (780,072) | (540,212) | (588,604) |
| Gross Profit | 550,323 | 3.945% | 1,084,212 | 997,186 | 872,579 | 1,579,976 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (1,751) | 2088.750% | (60,507) | (28,386) | (138) | 153 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 37,809 | -- | (255,291) | (585,219) | (109,466) | 210,276 | |
| Taxation | (9,954) | -- | 28,722 | 38,535 | 23,608 | (90,088) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 58 | -23.684% | 226 | 290 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 27,913 | -- | (226,343) | (546,394) | (85,858) | 120,188 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 6,886 | -57.097% | 30,602 | 53,469 | (52,155) | 45,819 |
| Depreciation & Amortisation | 125,152 | -25.759% | 315,210 | 334,840 | 224,672 | 200,975 |
| Directors' Emoluments | -- | -- | 4,889 | 4,456 | 4,085 | 2,344 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 6.000 | -- | -45.000 | -108.000 | -16.000 | 29.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 7.600 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | 26.207% |
| Cash flow per share ($) | -- | -- | 0.457 | (0.035) | (0.212) | 1.091 |
| NBV per share ($) | 1.413 | -- | 1.360 | 1.788 | 3.008 | 3.266 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 27,913 |
| %Change | -- |
| EPS / (LPS) | RMB 0.060 |
| NBV Per Share (¥) | RMB 1.413 |